Osimertinib, a third‐generation of EGFR TKI, induced higher CD47 expression in EGFRmut NSCLC HCC827 and NCI‐H1975 cells via NF‐κB signaling, and it also reduced PD‐L1 expression in cancer cells. This evidence concerns the gene NFKB1 and non-small cell lung carcinoma.